Drug Trial Radar · NCT07465835
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Feb 17, 2026
Primary completion
Jun 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Electra Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, two-part, multicenter study to evaluate ELA026 in participants ≥18 years old with relapsed/refractory TCM following any line of prior therapy who are eligible for investigational treatments.
Conditions
- T Cell Malignancies
Interventions
ELA026Drug
Weekly maintenance dosing via subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTs and treatment emergent adverse events (TEAEs), including serious adverse advents (SAEs)Time frame: DLTs from baseline to DLT window (35 days) and SAEs from baseline through end of safety follow up (approximately 28 weeks for those participants not continuing to optional extension phase)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Yale New Haven Hospital
New Haven, Connecticut · Recruiting
Emory University Hospital
Atlanta, Georgia · Recruiting
START, Midwest
Grand Rapids, Michigan · Recruiting
Memorial Sloan Kettering
New York, New York · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
MD Anderson
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.